BridgeBio (BBIO) says heart disease therapy Attruby beat Pfizer’s (PFE) rival drug, tafamidis, branded as Vyndamax, in a real ...
Pfizer faces some major LoE headwinds, but the stock is cheap and offers a large dividend, offering a solid total return ...
Pfizer's payout looks like a safe harbor in a rough market, but the patent clock is ticking and the balance sheet leaves ...
Pfizer Inc (PFE) announced an update on their ongoing clinical study. Pfizer Inc. is reporting new data from its Korean post-marketing study of Vyndamax capsules in transthyretin amyloid ...
Pfizer and Starbucks both raised their outlooks this summer, but a louder recovery and a quieter one are not the same thing, and for investors who need a portfolio to fund actual withdrawals, the ...
Z Through Phase III, Alnylam's Nucresiran Launch Plans, and the Full RNA-Silencing Competitive Landscape Reshaping hATTR TreatmentDublin, Sept. 04, 2026 (GLOBE NEWSWIRE) -- "Hereditary Transthyretin ...
AstraZeneca (AZN) on Friday released full data from a failed Phase 3 trial for its RNA-targeting silencer Wainua, developed with Ionis Pharma (IONS), for a rare heart condition called ATTR-CM, hurting ...
August 29, 2026I analyzed Pfizer once before in April. At that time, the stock price was $27.22, and looking at the figures—a ...
Not all older people need these medications, and they can carry increased risks. By Paula Span The scenario often unfolds like this: Medical researchers investigate a frequently used drug and report ...
A month has gone by since the last earnings report for BridgeBio Pharma (BBIO). Shares have lost about 10.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
New research spanning 51 brands and 66 indications finds access, affordability, continuity, and execution—not simply the number of services offered—differentiate stronger patient support ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results